PAREXEL FORMS EXCLUSIVE PARTNERSHIP WITH DOCTORS.NET.UK
BOSTON, MA, August 17, 2004 — PAREXEL International Limited, a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today announced that it has entered into an exclusive strategic collaboration with Doctors.net.uk, an online medical community, to further enhance its clinical services portfolio. Founded in 1998, Doctors.net.uk is the UK’s largest and most active online forum for UK-based medical professionals. The site currently numbers more than 100,000 members, including over 80% of UK-based physicians. Terms of the agreement were not disclosed.
Under the alliance, PAREXEL will leverage the capabilities of Doctors.net.uk to target and communicate with both general and highly specific doctor populations, offering PAREXEL the opportunity to access new clinical investigators and their patient populations. The alliance also provides Doctors.net.uk customers with access to the clinical trial expertise, advanced technologies, and project management skills of PAREXEL, one of the world’s largest bio/pharmaceutical outsourcing providers.
“The collaboration with Doctors.net.uk expands PAREXEL’s ability to tap into medical resources that exist across the UK, both on national and local levels,” said Carol Collins, Vice President, PAREXEL Clinical Research Services, Europe. “Additionally, our alliance with an established online organization assists clients seeking to identify new investigators or establish temporary patient referral networks.”
“Through our alliance with PAREXEL, we can now offer clients clinical research expertise in support of their activities,” stated Erik Jan Scholten, Commercial Director, Doctors.net.uk. “Our approach which combines clinical acumen with access to medical professionals will provide clients with crucial time-saving capabilities and should expedite project development.”
PAREXEL is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug
development and are designed to decrease time to peak sales. The technology portfolio includes web-based portal solutions and tracking tools, Interactive Voice Response Systems (IVRS), Clinical Trial Management Systems (CTMS), electronic diary and investigator database solutions. Perceptive also offers advanced medical diagnostics services to assess rapidly and objectively the safety and efficacy of new drugs, biologics, and medical devices in clinical trials. PAREXEL’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 51 locations throughout 35 countries around the world, and has 4,875 employees.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective owners and are hereby acknowledged.
Doctors.net.uk Limited (DNUK) was founded in 1998 to build a web-based forum for UK doctors. www.doctors.net.uk provides professional news, accredited continuing medical education and a spam free email service. It has 100,000 registered qualified medical subscribers, including over 30,000 GPs and 23,000 Hospital Consultants. In exchange for the free service doctors agree to take part in marketing and market research campaigns run via weekly email bulletins. Doctors.net.uk creates and builds web campaigns for pharmaceutical and healthcare companies, the Department of Health, the General Medical Council and medical colleges providing them with targeted access direct to doctors.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", "estimates", "projects" and similar expressions are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. PAREXEL's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts; PAREXEL's dependence on certain industries and clients; PAREXEL's ability to win new business, manage growth, and attract and retain employees; PAREXEL's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of PAREXEL’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2004 as filed with the SEC on May 13, 2004, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent PAREXEL’s estimates as of the date of this release. PAREXEL specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing PAREXEL’s estimates or views as of any date subsequent to the date of this press release.